Adagene Inc. (NASDAQ: ADAG) reported a net loss of $16.4 million for the six months ended June 30, 2026, widening from a $13.5 million loss in the corresponding period of FY25. The clinical-stage biotechnology company also reported a quarterly adjusted earnings per share (EPS) of $(0.20), missing the analyst consensus estimate of $(0.10) by 100 percent. This represents a 5.26 percent increase in losses compared to $(0.19) per share in the same period last year.

The capital raise extended the company’s cash runway into late 2028, providing funding for ongoing development of its lead program, muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody. During the period, Adagene recognized $1.6 million in net revenue, up from nil in H1FY25, reflecting fulfillment of performance obligations under collaboration agreements with Sanofi and Exelixis. Sales for the quarter were reported at $1.620 million.

Financial Performance

Operating expenses increased alongside revenue recognition. Research and development expenses rose 16.2% year-on-year to $14.0 million, reflecting continued clinical focus on muzastotug. Administrative expenses grew to $4.2 million from $3.7 million, primarily due to higher personnel and office-related costs.

Total borrowings from commercial banks in China decreased slightly to $5.7 million from $6.1 million at the end of FY25. These loans are primarily used to fund R&D activities in China.

What the Numbers Show

Non-GAAP net loss, which excludes share-based compensation expenses, stood at $14.2 million for the six months ended June 30, 2026, compared to $11.4 million in the prior year period. Share-based compensation expenses added approximately $2.1 million to the GAAP net loss, representing roughly 13% of the total reported loss. This indicates that while operational costs drove the majority of the deficit, non-cash equity compensation remains a significant component of the company’s expense structure. The miss on EPS estimates highlights the pressure on margins as R&D spending accelerates ahead of key clinical data readouts.

Pipeline and Corporate Updates

Adagene highlighted progress in its clinical pipeline, particularly for muzastotug in microsatellite stable colorectal cancer (MSS CRC) and hepatocellular carcinoma (HCC). A randomized Phase 2 trial in MSS CRC is ongoing, with results expected in the first half of 2027. Data presented at the American Association for Cancer Research (AACR) annual meeting showed promising efficacy for a triple combination therapy in first-line HCC.

The company also initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational immune-oncology agent through a collaboration with Sanofi. Additionally, Adagene appointed Peter Lebowitz, M.D., Ph.D., former Global Head of Oncology R&D for Johnson & Johnson, to its Scientific and Strategic Advisory Board.